Hepatic arterial infusion of polyethylene glycol drug-eluting beads for primary and metastatic liver cancer therapy

Camillo Aliberti, Riccardo Carandina, Donatella Sarti, Luca Mulazzani, Vincenzo Catalano, Alessandro Felicioli, Paolo Coschiera, Giammaria Fiorentini

Research output: Contribution to journalArticlepeer-review

Abstract

Background/Aim: Recently, there has been the launch of the new Polyethylene glycol (PEG) drug-eluting beads (LifePearl®) for transarterial chemoembolization. Their innovation is that PEG guarantees more compressibility, elasticity and maximizes beads' suspension time. We applied these beads for hepatic intra-arterial infusion of irinotecan or doxorubicin for the therapy of primary and metastatic liver cancer. Patients and Methods: We treated 20 consecutive patients, affected by unresectable primary liver cancer (PLC) or hepatic metastases (refractory to chemotherapy) using chemoembolization with doxorubicin or irinotecan pre-loaded Lifepearls. Results: Tumor response rate was >80% in most patients with 63% of complete and 37% of partial response. We observed no complications during the chemoembolization and no severe general drugrelated side-effects. Conclusion: Our data suggest that chemoembolization with LifePearl® is efficacious and safe for the treatment of liver cancer as indicated by good tolerability, quality of life and high tumor response.

Original languageEnglish
Pages (from-to)3515-3521
Number of pages7
JournalAnticancer Research
Volume36
Issue number7
Publication statusPublished - 2016

Keywords

  • Chemoembolization
  • Doxorubicin
  • Irinotecan
  • LIFDOX®
  • LIFIRI®
  • Liver cancer
  • Liver metastases
  • Polyethylene glycol drug-elutable beads

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Hepatic arterial infusion of polyethylene glycol drug-eluting beads for primary and metastatic liver cancer therapy'. Together they form a unique fingerprint.

Cite this